About Celcuity Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.celcuity.com/
Frequently Asked Questions
What is the 52-week range for CELC?
The 52-week high is $151.02 and the 52-week low is $44.42.
What is the P/E ratio for CELC?
The P/E ratio data is currently unavailable.
What is the dividend yield for CELC?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -244.61%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 45.90.
Analyst Recommendation Trends
Wall Street analyst consensus for CELC over the last few months:
Latest CELC News
Celcuity (CELC) Dropped, So What Is Behind Its Latest Move?
Celcuity (CELC) has moved into a new phase, with REVTORPYK now commercially available in the US for certain advanced breast cancer patients, paired with a support program that targets access, affordability, and treatment logistics. Despite REVTORPYK’s US launch and the recent appointment of seasoned finance leader David W. Gryska to Celcuity’s board, the share price has pulled back, with the 30 day share price return down 25.1% and the 1 year total shareholder return still up 42.7%. This...
Celcuity Appoints David Gryska To Its Board Of Directors
Mr. Gryska brings decades of strategic and financial leadership experience to Celcuity’s BoardMINNEAPOLIS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced the appointment of David W. Gryska to its Board of Directors. Mr. Gryska is a seasoned executive who brings over 35 years of strategic and financial leadership experience in
Why Celcuity Stock Was a Winner on Wednesday
Its first commercialized drug is now available for qualified patients.
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
REVTORPYK (gedatolisib) REVTORPYK (gedatolisib) vial and box REVTORPYK is indicated for patients with HR+/HER2- advanced breast cancer without a PIK3CA mutation detected following progression on or after at least one line of endocrine therapy in the metastatic settingREVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 to comprehensively blockade the PI3K/AKT/mTOR (“PAM”) pathwayIn the PIK3CA wild-type coho
Needham Maintains Buy on Celcuity, Lowers Price Target to $134
Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $140 to $134.
Celcuity Announces Commercial Availability Of REVTORPYK In U.S. For People With Hormone Receptor-Positive
Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that REVTORPYK™ (gedatolisib) is
Is Celcuity (CELC) Stock a Buy?
While early-stage biopharmaceutical firms typically lack historic multi-year revenue growth (0% 3-year CAGR at $0.00 TTM revenue), positive operating cash flow generation (-$153.3M TTM), or positive free cash flow conversion (-$192.3M TTM), Celcuity Inc. (NASDAQ:CELC) enters its commercial rollout backed by a balance sheet holding $754 million in cash and equivalents. Although historic return on […]
Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion
Initiate Faeth Therapeutics (FTH) at Buy: PIKTOR cancer program catalysts through 2027, $200M raise boosts runway but dilution risk.
JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157
JP Morgan analyst Anupam Rama initiates coverage on Celcuity (NASDAQ:CELC) with a Overweight rating and announces Price Target of $157.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
Celcuity Inc. (CELC) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 8:00 AM EDTCompany ParticipantsBrian Sullivan - Co-Founder, Chairman...
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-14 | Hahne Vicky | +10,000 | - | - |
| 2026-08-14 | Hahne Vicky | +16,000 | - | - |
| 2026-08-14 | Laing Lance G. | +10,000 | - | - |
| 2026-08-14 | Laing Lance G. | +20,000 | - | - |
| 2026-08-14 | Sullivan Brian F. | +120,000 | - | - |
| 2026-08-14 | Sullivan Brian F. | +80,000 | - | - |
| 2026-07-14 | BAKER BROS. ADVISORS LP | -2,838,632 | $102.5 | $290,959,780 |
| 2026-07-14 | BAKER BROS. ADVISORS LP | -261,368 | $102.5 | $26,790,220 |
| 2026-06-10 | Murphy Polly A. | +14,048 | - | - |
| 2026-06-10 | Murphy Polly A. | -14,048 | - | - |
| 2026-06-10 | Buller Richard E | +12,503 | - | - |
| 2026-06-10 | Buller Richard E | -12,503 | - | - |
| 2026-06-05 | Murphy Polly A. | +1,530 | - | - |
| 2026-06-05 | ROMP CHARLES R | +1,530 | - | - |
| 2026-06-05 | Furcht Leo | +1,530 | - | - |
| 2026-06-05 | Buller Richard E | +1,530 | - | - |
| 2026-06-05 | Dalvey David | +1,530 | - | - |
| 2026-06-05 | NIGON RICHARD | +1,530 | - | - |
| 2026-06-02 | Laing Lance G. | -1,000 | - | - |
| 2026-06-02 | Laing Lance G. | +1,000 | $9.89 | $9,890 |
| 2026-05-19 | Buller Richard E | +1,029 | - | - |
| 2026-05-19 | Buller Richard E | -1,029 | - | - |
| 2026-05-04 | Buller Richard E | -9,000 | - | - |
| 2026-05-04 | Buller Richard E | -365 | $143.2378 | $52,282 |
| 2026-05-04 | Buller Richard E | -2,825 | $142.0358 | $401,251 |
| 2026-05-04 | Buller Richard E | -2,301 | $141.0271 | $324,503 |
| 2026-05-04 | Buller Richard E | -1,670 | $139.5832 | $233,104 |
| 2026-05-04 | Buller Richard E | -550 | $138.9955 | $76,448 |
| 2026-05-04 | Buller Richard E | -1,289 | $137 | $176,593 |
| 2026-05-04 | Buller Richard E | +9,000 | $5.1 | $45,900 |
| 2026-05-04 | Dalvey David | -25,000 | $140.68 | $3,517,000 |
| 2026-04-09 | NIGON RICHARD | -10,000 | - | - |
| 2026-03-31 | Buller Richard E | -3,000 | - | - |
| 2026-03-31 | Buller Richard E | -675 | $110.8268 | $74,808 |
| 2026-03-31 | Buller Richard E | -2,325 | $110.1057 | $255,996 |
| 2026-03-31 | Buller Richard E | +3,000 | $5.1 | $15,300 |
| 2026-02-11 | ROMP CHARLES R | +215 | - | - |
| 2026-01-27 | Dalvey David | -20,000 | $120.0269 | $2,400,538 |
| 2025-12-15 | NIGON RICHARD | -19,975 | - | - |
| 2025-12-05 | Buller Richard E | -3,000 | - | - |
| 2025-12-05 | Buller Richard E | -1,510 | $106.0353 | $160,113 |
| 2025-12-05 | Buller Richard E | -1,490 | $105.3398 | $156,956 |
| 2025-12-05 | Buller Richard E | +3,000 | $5.5 | $16,500 |
| 2025-12-04 | Furcht Leo | -250 | - | - |
| 2025-12-04 | Furcht Leo | +250 | $7.6 | $1,900 |
| 2025-12-02 | Buller Richard E | -500 | - | - |
| 2025-12-01 | Buller Richard E | -1,100 | - | - |
| 2025-12-01 | Buller Richard E | -1,100 | $98.1349 | $107,948 |
| 2025-12-01 | Buller Richard E | +1,100 | $14.83 | $16,313 |
| 2025-11-21 | Dalvey David | -15,000 | $100.0011 | $1,500,017 |
| 2025-11-20 | Buller Richard E | -3,900 | - | - |
| 2025-11-20 | Buller Richard E | -3,900 | $96.732 | $377,255 |
| 2025-11-20 | Buller Richard E | +3,900 | $14.83 | $57,837 |
| 2025-11-19 | Buller Richard E | -500 | - | - |